vs

Side-by-side financial comparison of NATURES SUNSHINE PRODUCTS INC (NATR) and Udemy, Inc. (UDMY). Click either name above to swap in a different company.

Udemy, Inc. is the larger business by last-quarter revenue ($194.0M vs $123.8M, roughly 1.6× NATURES SUNSHINE PRODUCTS INC). NATURES SUNSHINE PRODUCTS INC runs the higher net margin — 3.3% vs -1.2%, a 4.5% gap on every dollar of revenue. On growth, NATURES SUNSHINE PRODUCTS INC posted the faster year-over-year revenue change (4.7% vs -3.0%). Udemy, Inc. produced more free cash flow last quarter ($15.0M vs $7.6M). Over the past eight quarters, NATURES SUNSHINE PRODUCTS INC's revenue compounded faster (5.6% CAGR vs -0.7%).

Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.

Udemy is a US-based education technology company. Founded as a massive open online course (MOOC) provider in 2010 by Eren Bali, Gagan Biyani, and Oktay Caglar; the company is based in San Francisco, California, with offices in the United States, Australia, India, Ireland, Mexico and Turkey. Its education platform allows both the creation and sharing of online courses. By early 2025, Udemy claimed to have millions of individual users. Courses are typically video-based and on-demand.

NATR vs UDMY — Head-to-Head

Bigger by revenue
UDMY
UDMY
1.6× larger
UDMY
$194.0M
$123.8M
NATR
Growing faster (revenue YoY)
NATR
NATR
+7.7% gap
NATR
4.7%
-3.0%
UDMY
Higher net margin
NATR
NATR
4.5% more per $
NATR
3.3%
-1.2%
UDMY
More free cash flow
UDMY
UDMY
$7.4M more FCF
UDMY
$15.0M
$7.6M
NATR
Faster 2-yr revenue CAGR
NATR
NATR
Annualised
NATR
5.6%
-0.7%
UDMY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NATR
NATR
UDMY
UDMY
Revenue
$123.8M
$194.0M
Net Profit
$4.1M
$-2.3M
Gross Margin
72.5%
66.0%
Operating Margin
4.3%
-1.8%
Net Margin
3.3%
-1.2%
Revenue YoY
4.7%
-3.0%
Net Profit YoY
1379.4%
76.4%
EPS (diluted)
$0.23
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NATR
NATR
UDMY
UDMY
Q4 25
$123.8M
$194.0M
Q3 25
$128.3M
$195.7M
Q2 25
$114.8M
$199.9M
Q1 25
$113.2M
$200.3M
Q4 24
$118.2M
$199.9M
Q3 24
$114.6M
$195.4M
Q2 24
$110.6M
$194.4M
Q1 24
$111.0M
$196.8M
Net Profit
NATR
NATR
UDMY
UDMY
Q4 25
$4.1M
$-2.3M
Q3 25
$5.3M
$1.6M
Q2 25
$5.3M
$6.3M
Q1 25
$4.7M
$-1.8M
Q4 24
$-321.0K
$-9.9M
Q3 24
$4.3M
$-25.3M
Q2 24
$1.3M
$-31.8M
Q1 24
$2.3M
$-18.3M
Gross Margin
NATR
NATR
UDMY
UDMY
Q4 25
72.5%
66.0%
Q3 25
73.3%
65.9%
Q2 25
71.7%
66.1%
Q1 25
72.1%
64.6%
Q4 24
72.0%
63.6%
Q3 24
71.3%
63.0%
Q2 24
71.4%
62.3%
Q1 24
71.2%
61.2%
Operating Margin
NATR
NATR
UDMY
UDMY
Q4 25
4.3%
-1.8%
Q3 25
7.0%
-0.1%
Q2 25
3.7%
2.0%
Q1 25
5.4%
-2.2%
Q4 24
3.8%
-5.8%
Q3 24
4.6%
-15.1%
Q2 24
5.1%
-13.1%
Q1 24
4.2%
-11.5%
Net Margin
NATR
NATR
UDMY
UDMY
Q4 25
3.3%
-1.2%
Q3 25
4.2%
0.8%
Q2 25
4.6%
3.1%
Q1 25
4.2%
-0.9%
Q4 24
-0.3%
-4.9%
Q3 24
3.8%
-12.9%
Q2 24
1.2%
-16.4%
Q1 24
2.1%
-9.3%
EPS (diluted)
NATR
NATR
UDMY
UDMY
Q4 25
$0.23
$-0.01
Q3 25
$0.30
$0.01
Q2 25
$0.28
$0.04
Q1 25
$0.25
$-0.01
Q4 24
$-0.02
$-0.06
Q3 24
$0.23
$-0.17
Q2 24
$0.07
$-0.21
Q1 24
$0.12
$-0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NATR
NATR
UDMY
UDMY
Cash + ST InvestmentsLiquidity on hand
$93.9M
$358.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$161.6M
$210.5M
Total Assets
$261.1M
$617.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NATR
NATR
UDMY
UDMY
Q4 25
$93.9M
$358.7M
Q3 25
$95.6M
$371.2M
Q2 25
$81.3M
$392.0M
Q1 25
$86.5M
$357.0M
Q4 24
$84.7M
$354.4M
Q3 24
$78.7M
$357.1M
Q2 24
$68.7M
$420.9M
Q1 24
$77.8M
$430.7M
Total Debt
NATR
NATR
UDMY
UDMY
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
$2.1M
Stockholders' Equity
NATR
NATR
UDMY
UDMY
Q4 25
$161.6M
$210.5M
Q3 25
$166.7M
$221.8M
Q2 25
$163.7M
$233.4M
Q1 25
$167.1M
$209.4M
Q4 24
$161.0M
$197.4M
Q3 24
$162.6M
$196.3M
Q2 24
$156.4M
$252.3M
Q1 24
$159.7M
$296.5M
Total Assets
NATR
NATR
UDMY
UDMY
Q4 25
$261.1M
$617.7M
Q3 25
$264.8M
$618.9M
Q2 25
$254.9M
$644.0M
Q1 25
$252.7M
$639.0M
Q4 24
$240.9M
$605.6M
Q3 24
$245.3M
$608.9M
Q2 24
$235.8M
$671.9M
Q1 24
$247.3M
$708.5M
Debt / Equity
NATR
NATR
UDMY
UDMY
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.01×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NATR
NATR
UDMY
UDMY
Operating Cash FlowLast quarter
$9.9M
$15.5M
Free Cash FlowOCF − Capex
$7.6M
$15.0M
FCF MarginFCF / Revenue
6.1%
7.7%
Capex IntensityCapex / Revenue
1.9%
0.3%
Cash ConversionOCF / Net Profit
2.41×
TTM Free Cash FlowTrailing 4 quarters
$28.8M
$81.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NATR
NATR
UDMY
UDMY
Q4 25
$9.9M
$15.5M
Q3 25
$18.5M
$15.7M
Q2 25
$4.3M
$44.2M
Q1 25
$2.6M
$12.2M
Q4 24
$12.2M
$9.6M
Q3 24
$9.6M
$-6.1M
Q2 24
$1.3M
$28.6M
Q1 24
$2.2M
$21.0M
Free Cash Flow
NATR
NATR
UDMY
UDMY
Q4 25
$7.6M
$15.0M
Q3 25
$16.8M
$15.1M
Q2 25
$3.0M
$41.9M
Q1 25
$1.5M
$9.8M
Q4 24
$10.0M
$8.4M
Q3 24
$7.9M
$-6.7M
Q2 24
$-2.0M
$28.2M
Q1 24
$-1.5M
$20.8M
FCF Margin
NATR
NATR
UDMY
UDMY
Q4 25
6.1%
7.7%
Q3 25
13.1%
7.7%
Q2 25
2.6%
21.0%
Q1 25
1.3%
4.9%
Q4 24
8.5%
4.2%
Q3 24
6.9%
-3.4%
Q2 24
-1.9%
14.5%
Q1 24
-1.4%
10.6%
Capex Intensity
NATR
NATR
UDMY
UDMY
Q4 25
1.9%
0.3%
Q3 25
1.3%
0.3%
Q2 25
1.2%
1.1%
Q1 25
1.0%
1.2%
Q4 24
1.9%
0.6%
Q3 24
1.5%
0.3%
Q2 24
3.0%
0.2%
Q1 24
3.3%
0.1%
Cash Conversion
NATR
NATR
UDMY
UDMY
Q4 25
2.41×
Q3 25
3.46×
9.58×
Q2 25
0.81×
7.06×
Q1 25
0.55×
Q4 24
Q3 24
2.21×
Q2 24
0.97×
Q1 24
0.94×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NATR
NATR

Other$68.1M55%
General Health Products$20.2M16%
Digestive Products$13.8M11%
Cardiovascular Products$12.1M10%
Personal Care Products$4.4M4%
Immunity Products$3.1M3%
Weight Management Products$2.1M2%

UDMY
UDMY

Segment breakdown not available.

Related Comparisons